{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:53:32Z","timestamp":1783338812345,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113589","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:12:26Z","timestamp":1706919146000},"page":"113589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-8036","authenticated-orcid":false,"given":"Lo\u00efc","family":"Mourey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Tames","family":"Rainho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Carril-Ajuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Borchiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-4076","authenticated-orcid":false,"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionnel","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tantot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Naigeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113589_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.113589_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib3","unstructured":"SEER*Explorer Application n.d. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=630&data_type=5&graph_type=12&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&chk_age_range_141=141&chk_age_range_157=157&series=9&sex=1&race=1&prev_duration=1&advopt_precision=1&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1 (accessed February 14, 2023)."},{"key":"10.1016\/j.ejca.2024.113589_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113589_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113589_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113589_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199642","article-title":"Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab expanded access program (EAP) in Italy","volume":"13","author":"Vitale","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2024.113589_bib8","first-page":"CD013798","article-title":"First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"5","author":"Aldin","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2024.113589_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2024.113589_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","article-title":"Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism","volume":"100","author":"Dobbs","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ejca.2024.113589_bib11","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.2147\/OTT.S165368","article-title":"The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis","volume":"11","author":"Li","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejca.2024.113589_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","article-title":"Immune senescence, epigenetics and autoimmunity","volume":"196","author":"Ray","year":"2018","journal-title":"Clin Immunol Orlando Fla"},{"key":"10.1016\/j.ejca.2024.113589_bib13","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1200\/JCO.2022.40.16_suppl.4552","article-title":"Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): a validation study within the NIVOREN GETUG-AFU 26 translational study","volume":"40","author":"Carril-Ajuria","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.6_suppl.379","article-title":"The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 translational study","volume":"40","author":"Carril","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib15","article-title":"Efficacy and safety of nivolumab for advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10147-020-01693-y","article-title":"Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes","volume":"25","author":"Numakura","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","article-title":"Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase IIIb\/IV CheckMate 374 study","volume":"18","author":"Vogelzang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2024.113589_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab first-line therapy for elderly, frail hodgkin lymphoma patients: niviniho, a lysa phase II study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.113589_bib19","first-page":"126","article-title":"Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme","volume":"100","author":"Grossi","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2024.113589_bib20","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2016.34.15_suppl.10009","article-title":"Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)","volume":"34","author":"Friedman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib21","first-page":"1628","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ejca.2024.113589_bib22","first-page":"68","article-title":"Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours","volume":"95","author":"Herin","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2024.113589_bib23","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(18)30125-6","article-title":"Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology","volume":"19","author":"Kanesvaran","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2022.103652","article-title":"The roles and therapeutic applications of cytokines in endometrial cancer","volume":"152","author":"Azadehrah","year":"2022","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.ejca.2024.113589_bib25","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis","volume":"10","author":"Browning","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2024.113589_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12885-017-3310-9","article-title":"Circulating blood levels of IL-6, IFN-\u03b3, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study","volume":"17","author":"S\u00e1nchez-Zauco","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.113589_bib27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1189\/jlb.0506297","article-title":"The role of cytokines in hepatocellular carcinoma","volume":"80","author":"Budhu","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2024.113589_bib28","doi-asserted-by":"crossref","first-page":"14489","DOI":"10.1002\/jcp.28252","article-title":"Inflammatory cytokines in bladder cancer","volume":"234","author":"Shadpour","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejca.2024.113589_bib29","article-title":"Serum cytokine profiles of Melanoma patients and their association with tumor progression and metastasis","volume":"2021","author":"Wang","year":"2021","journal-title":"J Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2024.113589_bib31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.113589_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2024.113589_bib33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/ijms19041057","article-title":"Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer","volume":"19","author":"Kong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2024.113589_bib34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/92.16.1329","article-title":"Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis","volume":"92","author":"Byrne","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.113589_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101814","article-title":"Immune aging - a mechanism in autoimmune disease","volume":"69","author":"Zheng","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ejca.2024.113589_bib36","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113589_bib37","doi-asserted-by":"crossref","unstructured":"B D, Jn E, L E, H S. Grading of renal cell carcinoma. Histopathology 2019;74. https:\/\/doi.org\/10.1111\/his.13735.","DOI":"10.1111\/his.13735"},{"key":"10.1016\/j.ejca.2024.113589_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jgo.2020.09.009","article-title":"Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience","volume":"12","author":"Pierantoni","year":"2021","journal-title":"J Geriatr Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:44:03Z","timestamp":1760733843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":38,"alternative-id":["S0959804924000650"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113589","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113589"}}